Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GBM CSCs were detected with CD133/1 and CD111 antibodies after co-culture studies.
|
23737374 |
2013 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Because AC133 and 293C antibodies do not detect all CD133 variants in glioblastoma cells, alternate detection methods need to be utilized for complete analysis of CD133 expression and for accurately determining the relationship between CD133 and cancer stem-like cells.
|
20428792 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
|
19468690 |
2009 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD9 silencing in three CD133+ glioblastoma cell lines (NCH644, NCH421k and NCH660h) led to decreased cell proliferation, survival, invasion, and self-renewal ability, and altered expression of the stem-cell markers CD133, nestin and SOX2.
|
26573230 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that CD133+ glioblastoma cells presenting stem-cell properties may express pro-vascular molecules allowing them to form blood vessels de novo.
|
20375132 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, we identified the crossreactivity of CD133 and MDR1 in a surgical specimen of GBM.
|
19832037 |
2009 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
WIP knockdown from mtp53-expressing glioblastoma and breast cancer cells (BCC) greatly reduced proliferation and growth capacity of cancer stem cell (CSC)-like cells and decreased CSC-like markers (CD133, CD44 or YAP/TAZ). mtp53 overexpression in human astrocytes enhanced their proliferative capacity in suspension culture and increased expression of CSC markers and WIP.
|
28166194 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We reported that WIP knockdown in mtp53-expressing glioblastoma greatly reduced proliferation and growth capacity of cancer stem cell (CSC)-like cells and decreased CSC-like markers, such as hyaluronic acid receptor (CD44), prominin-1 (CD133), yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ).
|
29890731 |
2018 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we demonstrated that two functionally related microRNAs, miR-20a and -106a (miR-20a/106a), were capable of enhancing the invasiveness of CD133(+) glioma stem cells (GSCs) isolated from both glioblastoma cell line U87 and primary human glioma specimens.
|
24704830 |
2015 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, one recent report demonstrated that <i>LIS1</i> gene is preferentially expressed in CD133+ glioblastoma cells and may have also an important role in regulating CD133+ CSC in glioblastoma.
|
31750243 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
|
25749043 |
2015 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we characterize the expression and role of Bmi1 in primary minimally cultured human glioblastoma (GBM) patient isolates in CD133+ and CD133- sorted populations.
|
22265735 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the current study, miR-203 expression was reduced in CD133(+) GBM-SCs derived from six human GBM biopsies.
|
27484906 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that CSC concept is more complex than it was believed before, and CD133 could not define entire stem cell population within GBM.
|
23836332 |
2014 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, our data provide first evidence that CD133(+) CSC maintain only a subset of primary glioblastomas.
|
17483311 |
2007 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
|
22431923 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, the in vivo delivery of PU-PEI-miR145 alone significantly suppressed tumorigenesis with stemness, and synergistically improved the survival rate when used in combination with radiotherapy and temozolomide in orthotopic GBM-CD133(+)-transplanted immunocompromised mice.
|
22098779 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MTAP deficiency promotes glioma stem-like cell (GSC) formation with increased expression of <i>PROM1</i>/CD133 and enhanced tumorigenicity of GBM cells and is associated with poor prognosis in patients with GBM.
|
31040154 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133+ GSCs express significantly higher ASAH1 compared to CD133- GSCs and serum-cultured glioblastoma cell lines, such as U87MG.
|
29348854 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Growing CD133(+) cells sorted from three GB neurosphere cultures at 7% O(2) reduced their doubling time and increased the self-renewal potential as reflected by clonogenicity.
|
19372578 |
2009 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Flow cytometry analysis showed the presence of CD133(-) subpopulations expressing these markers in glioma cell lines and in primary cultures from human glioblastoma (GBM) biopsies.
|
20460538 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report that our in vitro model enriched for a CD15+/CD133- BTSC population, mirroring the phenotype of BTSCs in recurrent GBM.
|
26498281 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioblastomas (GBM) may contain a variable proportion of active cancer stem cells (CSCs) capable of self-renewal, of aggregating into CD133(+) neurospheres, and to develop intracranial tumors that phenocopy the original ones.
|
22174890 |
2011 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Co-immunofluorescence staining demonstrated the co-localization of CD133- and LGR5-positive cells in glioblastoma tissue sections.
|
22805276 |
2013 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, by FACS analysis we determined the percentage of CD133 positive cells in three primary cultured cell lines established from glioblastoma patients 10.2%, 69.7% and 27.5%, respectively.
|
17140455 |
2006 |